Oxycodone
[SH4:p116; PI on MIMS]
Usage
Moderate to severe pain
Structure
- Semisynthetic narcotic analgesic
- Derived from opium alkaloid thebaine
- Chemical name is 14-hydroxydihydrocodeinone
Pharmacodynamics
Potency
1 mg of oxycodone PO
= Morphine 2mg PO, or 1/3 mg IV
= Pethidine 10mg PO, or 2.5mg IV
= Codeine 7mg PO (approx)
* [PI: OxyContin]
Mechanism of action
- Agonist at MOP receptors
- Weak agonist at DOP and KOP receptors
Effects
Similar to other opioid agonists
Side effects
- High abuse potential
- Risk of tempering
* Crushing and powdering for IV or intranasal use
Overdose
Symptoms and signs
- Respiratory depression
- Somnolence
- Eventually coma and skeletal muscle flaccidity
- Rhabdomyolysis leading to renal failure has been reported
- Pulmonary oedema
Pharmacokinetics
Absorption
- High oral bioavailability = up to 87% after PO
* Morphine PO bioavailability is about 30%
- Absorption of OxyContin is biphasic
* Initial absorption of about 40% within first hour
* than more controlled absorption
Metabolism
- Extensively metabolised to noroxycodone
* By CYP3A isoenzymes
- Also some metabolised to oxymorphone
* By CYP2D6
Elimination
Both metabolites eventually undergo glucuronidation
Action profile
Endone
- Analgesic effect occurs within 10-15 minutes
- Peak action in 30-60 minutes
- Persists for 3-6 hours
* May be shorter if tolerance
- Elimination half-life = 2-4 hours
OxyContin
Maximal plasma concentration in about 3 hours
Half-life = 6.5 hours
Pharmaceutics
Formulation
- Active
* Oxycodone hydrochloride
- Inactive
* Stearic acid
* Microcrystalline cellulose
* Anhydrous lactose
Clinical
Interactions
Can potentiate anticoagulant activity of coumarin derivatives (e.g. warfarin)
Effects of oxycodone is
* Increased by alkalising agents
* Decreased by acidifying agents
Special considerations
- Reduce doses in elderly, hepatic or renal impairments
- Females have 25% higher plasma oxycodone concentration
* Reasons unknown
- Not recommended for children under 12 y.o.